On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).